DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors [Yahoo! Finance]
DiaMedica Therapeutics Inc. (DMAC)
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O'Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, where under his leadership the company grew from a $40 million valuation upon him joining the company to being acquired by Johnson & Johnson for $2 billion just 14 months later. His expertise spans across capital markets, licensing transactions, business development, corporate strategy, clinical development and regulatory compliance, making him a valuable addition to DiaMedica's Board. "DiaMedica
Show less
Read more
Impact Snapshot
Event Time:
DMAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMAC alerts
High impacting DiaMedica Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DMAC
News
- DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDABusiness Wire
- DiaMedica Therapeutics (NASDAQ:DMAC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
- DiaMedica signals revised ReMEDy2 trial timeline and expansion cohort completion for DM199 amid cash runway into 2027 [Seeking Alpha]Seeking Alpha
- DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
DMAC
Earnings
- 11/12/25 - Miss
DMAC
Sec Filings
- 12/18/25 - Form 8-K
- 12/8/25 - Form 4
- 11/25/25 - Form 4
- DMAC's page on the SEC website